JP2019517589A5 - - Google Patents

Download PDF

Info

Publication number
JP2019517589A5
JP2019517589A5 JP2019516103A JP2019516103A JP2019517589A5 JP 2019517589 A5 JP2019517589 A5 JP 2019517589A5 JP 2019516103 A JP2019516103 A JP 2019516103A JP 2019516103 A JP2019516103 A JP 2019516103A JP 2019517589 A5 JP2019517589 A5 JP 2019517589A5
Authority
JP
Japan
Prior art keywords
cells
car
dose
subject
expressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019516103A
Other languages
English (en)
Japanese (ja)
Other versions
JP7139318B2 (ja
JP2019517589A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/036231 external-priority patent/WO2017214207A2/en
Publication of JP2019517589A publication Critical patent/JP2019517589A/ja
Publication of JP2019517589A5 publication Critical patent/JP2019517589A5/ja
Priority to JP2021199037A priority Critical patent/JP2022033929A/ja
Application granted granted Critical
Publication of JP7139318B2 publication Critical patent/JP7139318B2/ja
Priority to JP2023189795A priority patent/JP2023184646A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019516103A 2016-06-06 2017-06-06 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法 Active JP7139318B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021199037A JP2022033929A (ja) 2016-06-06 2021-12-08 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法
JP2023189795A JP2023184646A (ja) 2016-06-06 2023-11-07 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662346547P 2016-06-06 2016-06-06
US62/346,547 2016-06-06
US201662417292P 2016-11-03 2016-11-03
US62/417,292 2016-11-03
US201662429737P 2016-12-03 2016-12-03
US62/429,737 2016-12-03
PCT/US2017/036231 WO2017214207A2 (en) 2016-06-06 2017-06-06 Methods for the treatment of b cell malignancies using adoptive cell therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021199037A Division JP2022033929A (ja) 2016-06-06 2021-12-08 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法

Publications (3)

Publication Number Publication Date
JP2019517589A JP2019517589A (ja) 2019-06-24
JP2019517589A5 true JP2019517589A5 (https=) 2020-07-16
JP7139318B2 JP7139318B2 (ja) 2022-09-20

Family

ID=59227902

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019516103A Active JP7139318B2 (ja) 2016-06-06 2017-06-06 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法
JP2021199037A Pending JP2022033929A (ja) 2016-06-06 2021-12-08 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法
JP2023189795A Pending JP2023184646A (ja) 2016-06-06 2023-11-07 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021199037A Pending JP2022033929A (ja) 2016-06-06 2021-12-08 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法
JP2023189795A Pending JP2023184646A (ja) 2016-06-06 2023-11-07 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法

Country Status (11)

Country Link
US (2) US20200016199A1 (https=)
EP (1) EP3463437A2 (https=)
JP (3) JP7139318B2 (https=)
KR (3) KR102644950B1 (https=)
CN (1) CN109562151A (https=)
AU (1) AU2017277396B2 (https=)
BR (1) BR112018074406A2 (https=)
CA (1) CA3024725A1 (https=)
MA (1) MA45341A (https=)
MX (2) MX2018014911A (https=)
WO (1) WO2017214207A2 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX392487B (es) 2014-10-20 2025-03-21 Juno Therapeutics Inc Métodos y composiciones para dosificación en terapia celular adoptiva.
ES2818103T3 (es) 2015-01-16 2021-04-09 Juno Therapeutics Inc Anticuerpos y receptores de antígenos quiméricos específicos para ROR1
EP4006056A1 (en) 2016-02-02 2022-06-01 Fred Hutchinson Cancer Research Center Anti-ror1 antibodies and uses thereof
JP2019532997A (ja) * 2016-11-03 2019-11-14 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法とｂｔｋ阻害剤との併用療法
CA3045339A1 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
BR112019017767A2 (pt) 2017-02-27 2020-04-07 Juno Therapeutics Inc composições, artigos de fabricação e métodos relacionados à dosagem em terapia celular
MX2019010906A (es) 2017-03-14 2020-02-12 Juno Therapeutics Inc Metodos para almacenamiento criogenico.
AU2018275894B2 (en) 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
US12350312B2 (en) 2017-09-06 2025-07-08 Fred Hutchinson Cancer Center Methods for improving adoptive cell therapy
US11771718B2 (en) 2017-10-18 2023-10-03 Precigen, Inc. Polypeptide compositions comprising spacers
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
US12258580B2 (en) 2017-11-01 2025-03-25 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
WO2019200347A1 (en) * 2018-04-13 2019-10-17 Fred Hutchinson Cancer Research Center Methods for adoptive cell therapy targeting ror1
KR20210044736A (ko) * 2018-05-03 2021-04-23 주노 쎄러퓨티크스 인코퍼레이티드 키메라 항원 수용체(ｃａｒ) ｔ세포 요법과 키나제 억제제의 조합요법
US12516099B2 (en) 2018-08-09 2026-01-06 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
WO2020092475A1 (en) * 2018-10-31 2020-05-07 The Children's Hospital Of Philadelphia T cells from lymphatic fluid for diagnostic and therapeutic use
CA3117978A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
CN113692285A (zh) * 2018-11-30 2021-11-23 朱诺治疗学股份有限公司 在过继细胞疗法中给药和治疗b细胞恶性肿瘤的方法
PT3886875T (pt) * 2018-11-30 2024-06-27 Juno Therapeutics Inc Métodos para tratamento utilizando terapia celular adotiva
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
CN111825769B (zh) * 2019-04-16 2022-03-25 上海科技大学 一种泛素化缺失的嵌合抗原受体及其用途
WO2020261219A1 (en) * 2019-06-27 2020-12-30 Crispr Therapeutics Ag Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
MX2022006715A (es) * 2019-12-06 2022-09-23 Juno Therapeutics Inc Metodos relacionados con toxicidad y respuesta asociada con terapia celular para tratar neoplasias malignas de celulas b.
EP4093433A1 (en) * 2020-01-24 2022-11-30 Juno Therapeutics, Inc. Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy
IL295384B1 (en) * 2020-02-12 2026-04-01 Juno Therapeutics Inc T-cell preparations with chimeric antigen receptor directed against CD19 and methods and uses thereof
EP4153616A4 (en) * 2020-05-18 2024-08-21 Robert Sackstein COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES
US20230263890A1 (en) * 2020-06-05 2023-08-24 Tessa Therapeutics Ltd. Treatment of cd30-positive cancer
WO2021260657A1 (en) * 2020-06-26 2021-12-30 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
CA3195201A1 (en) * 2020-10-20 2022-04-28 Mark Benton Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
WO2022197762A1 (en) * 2021-03-16 2022-09-22 Memorial Sloan-Kettering Cancer Center Methods of personalized preconditioning for cell therapy
RU2758126C1 (ru) * 2021-04-02 2021-10-26 федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации Способ прогнозирования развития рецидива диффузной В-крупноклеточной лимфомы
WO2022226355A2 (en) * 2021-04-23 2022-10-27 Myeloid Therapeutics, Inc. Compositions and methods for conditioning patients for cell therapy
TW202307210A (zh) * 2021-06-01 2023-02-16 瑞士商諾華公司 Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
WO2025006561A2 (en) * 2023-06-27 2025-01-02 Nkarta, Inc. Methods for treatment using cd19-directed immunotherapies

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (https=) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
AU4746590A (en) 1988-12-28 1990-08-01 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
EP1109921A4 (en) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
SI2856876T1 (en) 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
ES2660180T3 (es) 2007-12-07 2018-03-21 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
EP2331566B1 (en) 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
PL2918604T3 (pl) * 2008-11-07 2018-05-30 Amgen Research (Munich) Gmbh Leczenie pediatrycznej ostrej białaczki limfoblastycznej
TR201904484T4 (tr) 2009-11-03 2019-05-21 Hope City Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt).
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
CN104080797A (zh) 2011-11-11 2014-10-01 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
CA2861491C (en) 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
EP2844743B1 (en) 2012-05-03 2021-01-13 Fred Hutchinson Cancer Research Center Enhanced affinity t cell receptors and methods for making the same
HRP20230297T1 (hr) * 2012-07-13 2023-05-12 The Trustees Of The University Of Pennsylvania UPRAVLJANJE TOKSIČNOŠĆU ZA ANTI-TUMORSKO DJELOVANJE CAR-a
BR122020002986A8 (pt) * 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus

Similar Documents

Publication Publication Date Title
JP2019517589A5 (https=)
Wang et al. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
JP7682820B2 (ja) Ｃａｒの抗腫瘍活性のための毒性管理
Pianko et al. Immune checkpoint blockade for hematologic malignancies: a review
Hude et al. The emerging role of immune checkpoint inhibition in malignant lymphoma
Fong et al. Anti–cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment
JP2024059707A (ja) 腫瘍微小環境の特性を使用するキメラ受容体ｔ細胞治療
JP2024023318A (ja) 二重特異性抗体の組成物及びその使用方法
Honeychurch et al. Immuno-regulatory antibodies for the treatment of cancer
Cabo et al. Trial watch: immunostimulatory monoclonal antibodies for oncological indications
EP3548083A1 (en) Methods for modulation of car-t cells
Lanier et al. Immunotherapy approaches for hematological cancers
JP2020533962A5 (https=)
Katsin et al. CAR-T cell therapy for classical Hodgkin lymphoma
US20190287013A1 (en) Methods for determining dosing of a therapeutic agent and related treatments
JP7704748B2 (ja) 逐次抗ｃｄ１９治療
Lam et al. Pharmacokinetics and pharmacodynamics of immunotherapy
Iriyama Development and biomarkers of CD20/CD3 bispecific antibodies in diffuse large B-cell lymphoma
Chen et al. Natural Killer Cell Therapy in Ovarian Cancer: From Preclinical Potentials to Clinical Applications and Combination Strategies
WO2026096859A2 (en) Biomarkers related to immunotherapy efficacy
HK40116181A (en) Toxicity management for anti-tumor activity of cars
HK40116181B (en) Toxicity management for anti-tumor activity of cars
WO2025096517A1 (en) Factors for optimizing immunotherapy efficacy
HK40069741B (en) Toxicity management for anti-tumor activity of cars
HK40069741A (en) Toxicity management for anti-tumor activity of cars